Try our beta test site
862 studies found for:    Open Studies | "Prostatic Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
Condition: Prostatic Neoplasms
Intervention: Drug: Hyperpolarized Pyruvate (13C) Injection
22 Recruiting Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel;   Drug: Prednisone;   Drug: Enzalutamide
23 Recruiting Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Cabozantinib;   Drug: Docetaxel;   Drug: Prednisone
24 Recruiting Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Radiation: HypoIGRT
25 Recruiting Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Biological: PROSTVAC V/F;   Drug: Ipilimumab
26 Not yet recruiting Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET
Condition: Prostatic Neoplasms
Intervention: Drug: Somatostatin
27 Recruiting HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Condition: Prostatic Neoplasms
Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
28 Recruiting A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Niraparib;   Drug: Apalutamide
29 Recruiting A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Condition: Prostatic Neoplasms
Interventions: Biological: PF-06755992;   Biological: PF-06755990;   Device: TDS-IM Electroporation Device;   Biological: Tremelimumab;   Drug: Sunitinib;   Biological: PF-06801591
30 Recruiting Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention:
31 Recruiting Prostate Cancer Prospective Cohort
Condition: Prostate Cancer
Intervention:
32 Recruiting Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer
Conditions: Prostatic Neoplasms;   Prostate Cancer
Interventions: Biological: Autologus elutriated monocyte placebo vaccine;   Biological: ME TARP vaccine
33 Recruiting A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants
Condition: Prostatic Neoplasms
Intervention:
34 Recruiting A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland
Condition: Prostatic Neoplasms
Intervention: Radiation: 11C-Choline
35 Not yet recruiting Focal Therapy for Prostate Cancer
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention: Radiation: Brachytherapy
36 Recruiting CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer
Conditions: Prostate Cancer;   Prostatic Neoplasms
Interventions: Other: CEUS and targeted biopsies;   Other: MRI and targeted biopsies
37 Recruiting An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Condition: Prostatic Neoplasms
Intervention: Drug: Niraparib
38 Not yet recruiting PSMA PET/CT for Prostate Cancer
Conditions: Prostatic Neoplasms;   Prostate Cancer
Intervention: Drug: PSMA PET/CT scan
39 Recruiting IG-VMAT for Localized Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: hypofraction;   Radiation: convention
40 Not yet recruiting Nivolumab in Prostate Cancer With Mutations in DNA Repair Defects (ImmunoProst Trial)
Condition: Prostate Cancer
Intervention: Drug: Nivolumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.